Actinium Pharma To Present Preclinical Data Supporting ATNM-400's Broad Potential At 39th Annual Congress Of EANM
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal cancer data
Actinium Pharma is showing early test results for a new cancer medicine. This suggests the drug might work against different types of lung and colorectal cancer, which is what researchers hoped to find.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.